Who is sponsoring NCT04320030?

NCT04320030 is sponsored by Institut Cancerologie de l'Ouest.

What drugs are being tested in NCT04320030?

Interventions in NCT04320030: [18F]-DPA-714 PET/CT scan.

What condition does NCT04320030 study?

NCT04320030 studies Triple Negative Breast Cancer.

Is NCT04320030 still recruiting?

NCT04320030 is currently completed. Last updated 21 February 2023.

Last reviewed 2023-02-21 · How we verify

NCT04320030: EITHICS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

[18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers

Completed Phase 2 Last updated 21 February 2023

What this trial tests

Phase 2 trial testing [18F]-DPA-714 PET/CT scan in Triple Negative Breast Cancer in 13 participants. Completed in 21 July 2021.

Timeline

11 June 2020

Primary endpoint
21 July 2021

21 July 2021

Quick facts

Lead sponsor	Institut Cancerologie de l'Ouest
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	13
Start date	11 June 2020
Primary completion	21 July 2021
Estimated completion	21 July 2021
Sites	3 locations across France

Drugs / interventions tested

[18F]-DPA-714 PET/CT scan — full drug profile →

Conditions studied

Triple Negative Breast Cancer — all drugs for Triple Negative Breast Cancer →

Sponsor

Institut Cancerologie de l'Ouest — full company profile →

Who can join

18 and older, female only, with Triple Negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II study is assessing the correlation between M1/M2 macrophage polarization determined by tumor immunohistochemistry analysis and \[18F\]DPA-714 PET/CT binding (qualitative and texture analysis) in patients with operable triple negative breast cancer.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Dissection of pro-tumoral macrophage subtypes and immunosuppressive cells participating in M2 polarization.
Sezginer O, Unver N. · · 2024 · cited 68× · PMID 38935134 · DOI 10.1007/s00011-024-01907-3
Radiomics as a New Frontier of Imaging for Cancer Prognosis: A Narrative Review.
Reginelli A, Nardone V, Giacobbe G, Belfiore MP, et al · · 2021 · cited 39× · PMID 34679494 · DOI 10.3390/diagnostics11101796
Pilot Feasibility Study: 18 F-DPA-714 PET/CT Macrophage Imaging in Triple-Negative Breast Cancers (EITHICS).
Rousseau C, Metz R, Kerdraon O, Ouldamer L, et al · · 2024 · cited 6× · PMID 38913962 · DOI 10.1097/rlu.0000000000005338
European Association of Nuclear Medicine October 20-23, 2021 Virtual.
· 2021 · cited 5× · PMID 34559267 · DOI 10.1007/s00259-021-05547-1
Current Approaches of Nuclear Molecular Imaging in Breast Cancer.
Schäfer L, Altunay B, Heesch A, van Nijnatten T, et al · · 2025 · PMID 40647404 · DOI 10.3390/cancers17132105

Verify or expand the search:

Other recruiting trials for Triple Negative Breast Cancer

Currently open trials in the same condition.

NCT07533123 — A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H · Phase 3 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07340541 — Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies · Phase 2 · recruiting
NCT07281976 — A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer · Phase 1, PHASE2 · recruiting
NCT06225505 — Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) · NA · recruiting

Other Institut Cancerologie de l'Ouest trials

Trials by the same sponsor.

NCT06978296 — HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymp · NA · not yet recruiting
NCT06967987 — Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2- · Phase 2 · withdrawn
NCT06756802 — Reproductive Health in Breast Cancer Survivor · active not recruiting
NCT07007325 — Prospective Feasibility Pilot Study Evaluating the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small · EARLY_PHASE1 · not yet recruiting
NCT06994702 — Impact of the MRI Restraint System on the Quality of the Synthetic Scan for Intracranial Radiotherapy Treatment · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04320030 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Cancerologie de l'Ouest
Last refreshed: 21 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04320030.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing